TAVR safe for small degenerating bioprosthetic aortic valves: study
Outcomes were surprisingly good for such a challenging group of patients, expert says
Transcatheter aortic-valve replacement (TAVR) offers a safer solution for patients with failing surgical aortic bioprosthetic valves at high risk for reoperation, according to an observational post-market study.
Surgical aortic valve replacement has often been the treatment of choice, but degeneration of the bioprosthetic valve may require reoperation, Dr Didier Tchetche, of the Clinique Pasteur in France, and colleagues write in JACC Cardiovascular Interventions.
